All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Pierre Fenaux, Hôpital Saint-Louis, Paris, FR. We asked, Which subgroups of patients benefit most from a Venetoclax+Azacitidine (Ven+Aza) combination?
Which subgroups of patients benefit most from a Ven+Aza combination?
Fenaux explains the current use for Ven+Aza before outlining early efficacy data from trials investigating this combination for high-risk MDS, highlighting the effect on earlier response rates and preventing later myelosuppression. He then suggests further stratification of this subgroup, including karyotype and transplant eligibility. Finally, he proposes the possibility for new combination therapies to improve survival in MDS.
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How can...
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
During the EHA2021 Virtual Congress, the MDS Hub spoke with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What...
Subscribe to get the best content related to MDS delivered to your inbox